Purple Biotech (PPBT) Debt Ratio (2015 - 2016)
Purple Biotech (PPBT) posted quarterly Debt Ratio of 0.04 for Q4 2016, down 27.64% year-over-year from 0.05 in Q1 2016, and down 27.64% quarter-over-quarter from 0.05 in Q4 2015.
Purple Biotech (PPBT) Debt Ratio (2015 - 2016) Analysis & Trends
Purple Biotech (PPBT) has reported Debt Ratio for 2 consecutive years, with 0.04 the latest figure, recorded in Q4 2016.
- In Q4 2016, Debt Ratio fell 27.64% year-over-year to 0.04; the TTM figure through Dec 2016 stood at 0.04 (down 27.64% YoY), while the FY2016 annual figure was 0.04, down 27.64% from the prior year.
- Debt Ratio slipped to 0.04 in Q4 2016 per PPBT's latest filing, from 0.05 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.05 in Q4 2015 and bottomed at 0.04 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.26 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.47 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.03 |
| 10 | Purple Biotech | 133.62 | 133.62 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 0.04 |
| Dec 31, 2015 | 0.05 |